Literature DB >> 26223644

RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus.

Jessica R Spengler1, Jenish R Patel2, Ayan K Chakrabarti1, Marko Zivcec1, Adolfo García-Sastre3, Christina F Spiropoulou1, Éric Bergeron4.   

Abstract

UNLABELLED: In the cytoplasm, the retinoic acid-inducible gene I (RIG-I) senses the RNA genomes of several RNA viruses. RIG-I binds to viral RNA, eliciting an antiviral response via the cellular adaptor MAVS. Crimean-Congo hemorrhagic fever virus (CCHFV), a negative-sense RNA virus with a 5'-monophosphorylated genome, is a highly pathogenic zoonotic agent with significant public health implications. We found that, during CCHFV infection, RIG-I mediated a type I interferon (IFN) response via MAVS. Interfering with RIG-I signaling reduced IFN production and IFN-stimulated gene expression and increased viral replication. Immunostimulatory RNA was isolated from CCHFV-infected cells and from virion preparations, and RIG-I coimmunoprecipitation of infected cell lysates isolated immunostimulatory CCHFV RNA. This report serves as the first description of a pattern recognition receptor for CCHFV and highlights a critical signaling pathway in the antiviral response to CCHFV. IMPORTANCE: CCHFV is a tick-borne virus with a significant public health impact. In order for cells to respond to virus infection, they must recognize the virus as foreign and initiate antiviral signaling. To date, the receptors involved in immune recognition of CCHFV are not known. Here, we investigate and identify RIG-I as a receptor involved in initiating an antiviral response to CCHFV. This receptor initially was not expected to play a role in CCHFV recognition because of characteristics of the viral genome. These findings are important in understanding the antiviral response to CCHFV and support continued investigation into the spectrum of potential viruses recognized by RIG-I.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26223644      PMCID: PMC4580164          DOI: 10.1128/JVI.01643-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Antagonism of type I interferon responses by new world hantaviruses.

Authors:  Jessica R Levine; Joseph Prescott; Kyle S Brown; Sonja M Best; Hideki Ebihara; Heinz Feldmann
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

2.  Hantaan virus triggers TLR3-dependent innate immune responses.

Authors:  Wiebke Handke; Robin Oelschlegel; Renate Franke; Detlev H Krüger; Andreas Rang
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

3.  Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3.

Authors:  Wenwen Zeng; Ming Xu; Siqi Liu; Lijun Sun; Zhijian J Chen
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

4.  Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression.

Authors:  Zao-Zhong Su; Devanand Sarkar; Luni Emdad; Paola M Barral; Paul B Fisher
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

5.  Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus.

Authors:  Ida Andersson; Linda Bladh; Mehrdad Mousavi-Jazi; Karl-Eric Magnusson; Ake Lundkvist; Otto Haller; Ali Mirazimi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

6.  Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation.

Authors:  Min-Jung Kim; Sun-Young Hwang; Tadaatsu Imaizumi; Joo-Yeon Yoo
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

7.  RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection.

Authors:  A M A Nasirudeen; Hui Hui Wong; Peiling Thien; Shengli Xu; Kong-Peng Lam; Ding Xiang Liu
Journal:  PLoS Negl Trop Dis       Date:  2011-01-04

8.  Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction.

Authors:  Matthias Habjan; Ida Andersson; Jonas Klingström; Michael Schümann; Arnold Martin; Petra Zimmermann; Valentina Wagner; Andreas Pichlmair; Urs Schneider; Elke Mühlberger; Ali Mirazimi; Friedemann Weber
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

9.  Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5.

Authors:  Matthias Schulte; Michael Sorkin; Sammy Al-Benna; Jadwiga Stupka; Tobias Hirsch; Adrien Daigeler; Marco Rainer Kesting; Hans-Ulrich Steinau; Frank Jacobsen; Lars Steinstraesser
Journal:  Springerplus       Date:  2013-05-24

Review 10.  Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis.

Authors:  Friedemann Weber; Ali Mirazimi
Journal:  Cytokine Growth Factor Rev       Date:  2008-11-21       Impact factor: 7.638

View more
  20 in total

1.  Isolation, Characterization, and Phylogenetic Analysis of Two New Crimean-Congo Hemorrhagic Fever Virus Strains from the Northern Region of Xinjiang Province, China.

Authors:  Yanfang Zhang; Shu Shen; Yaohui Fang; Jinliang Liu; Zhengyuan Su; Jinhao Liang; Zhong Zhang; Qiaoli Wu; Cheng Wang; Abulikemu Abudurexiti; Zhihong Hu; Yujiang Zhang; Fei Deng
Journal:  Virol Sin       Date:  2018-03-08       Impact factor: 4.327

2.  Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.

Authors:  Florine E M Scholte; Marko Zivcec; John V Dzimianski; Michelle K Deaton; Jessica R Spengler; Stephen R Welch; Stuart T Nichol; Scott D Pegan; Christina F Spiropoulou; Éric Bergeron
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

3.  A RIG-I-like receptor directs antiviral responses to a bunyavirus and is antagonized by virus-induced blockade of TRIM25-mediated ubiquitination.

Authors:  Yuan-Qin Min; Yun-Jia Ning; Hualin Wang; Fei Deng
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

4.  In silico design and analyses of a multi-epitope vaccine against Crimean-Congo hemorrhagic fever virus through reverse vaccinology and immunoinformatics approaches.

Authors:  Akinyemi Ademola Omoniyi; Samuel Sunday Adebisi; Sunday Abraham Musa; James Oliver Nzalak; Zainab Mahmood Bauchi; Kerkebe William Bako; Oluwasegun Davis Olatomide; Richard Zachariah; Jens Randel Nyengaard
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 5.  Immunobiology of Crimean-Congo hemorrhagic fever.

Authors:  Sergio E Rodriguez; David W Hawman; Teresa E Sorvillo; T Justin O'Neal; Brian H Bird; Luis L Rodriguez; Éric Bergeron; Stuart T Nichol; Joel M Montgomery; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2022-01-11       Impact factor: 10.103

Review 6.  Host Cell Restriction Factors of Bunyaviruses and Viral Countermeasures.

Authors:  Solène Lerolle; Natalia Freitas; François-Loïc Cosset; Vincent Legros
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 7.  Crimean-Congo Hemorrhagic Fever: Tick-Host-Virus Interactions.

Authors:  Anna Papa; Katerina Tsergouli; Katerina Tsioka; Ali Mirazimi
Journal:  Front Cell Infect Microbiol       Date:  2017-05-26       Impact factor: 5.293

Review 8.  Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus.

Authors:  Marko Zivcec; Florine E M Scholte; Christina F Spiropoulou; Jessica R Spengler; Éric Bergeron
Journal:  Viruses       Date:  2016-04-21       Impact factor: 5.048

9.  Micropathogen Community Analysis in Hyalomma rufipes via High-Throughput Sequencing of Small RNAs.

Authors:  Jin Luo; Min-Xuan Liu; Qiao-Yun Ren; Ze Chen; Zhan-Cheng Tian; Jia-Wei Hao; Feng Wu; Xiao-Cui Liu; Jian-Xun Luo; Hong Yin; Hui Wang; Guang-Yuan Liu
Journal:  Front Cell Infect Microbiol       Date:  2017-08-15       Impact factor: 5.293

Review 10.  Protect this house: cytosolic sensing of viruses.

Authors:  Michael J McFadden; Nandan S Gokhale; Stacy M Horner
Journal:  Curr Opin Virol       Date:  2016-12-09       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.